Effects of lipid-lowering therapies on lipoprotein(a) levels in patients with dyslipidemia: a systematic review and network meta-analysis of 64 randomised controlled trials

Back

ESC Professional Premium Access

Effects of lipid-lowering therapies on lipoprotein(a) levels in patients with dyslipidemia: a systematic review and network meta-analysis of 64 randomised controlled trials

Session: Lp(a): the new risk factor

Topic: Drug therapy

Speaker: Mr E. Loh (Singapore, SG)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mr Enver De Wei Loh

Singapore (Singapore)

0 follower

8 more presentations in this session

Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: design, rationale, and first results of the Zabrze-Lip(a)R Registry

Speaker: Associate Professor K. Dyrbus (Zabrze, PL)

A sex-related analysis on the influence of lipoprotein(a) on primary cardiovascular disease prevention and its interplay with traditional lipid markers: results from a 20-year cohort study.

Speaker: Miss E. Damigou (Athens, GR)

Prognostic values of lipoprotein(a) levels for secondary prevention of acute coronary syndrome among patients who underwent primary percutaneous coronary intervention

Speaker: Doctor R. Okubo (Tokyo, JP)

Lipoprotein(a) levels and LPA genotypes are not associated with echocardiographic measures of left ventricular structure and function in the general population

Speaker: Doctor A. Reimer Jensen (Gentofte, DK)

Lipoprotein(a) and cardiovascular prognosis of familial dyslipidemias: data from a 10-year follow-up study

Speaker: Doctor I. Andrikou (Athens, GR)

Access the full session

Lp(a): the new risk factor

Speakers: Mr E. Loh, Associate Professor K. Dyrbus, Miss E. Damigou, Doctor R. Okubo, Doctor A. Reimer Jensen...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources